The emerging role of psilocybin and MDMA in the treatment of mental illness
Hartej Gill, Barjot Gill, David Chen‐li, Sabine El‐halabi, Nelson B. Rodrigues, S. Danielle, Orly Lipsitz, Yena Lee, Joshua D. Rosenblat, Amna Majeed, Rodrigo B. Mansur, Flora Nasri, Roger Ho, Roger S. McIntyre
Expert Review of Neurotherapeutics September 21, 2020 DOI: 10.1080/14737175.2020.1826931 via OpenAlex
Summary
AI-generated from the abstractPsychedelics like psilocybin and MDMA show promise as a new type of therapy for mental health disorders. Evidence suggests they may work with just one dose, produce rapid effects, and be effective for treatment-resistant conditions, possibly serving as a standalone treatment. More clinical trials are needed to test their safety, tolerability, and effectiveness in real-world patient populations.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA Psilocybin |
| Keywords | Mental illness Psychiatry Mental health |
| Citations | 62 |
| Key finding | Psychedelics may offer a single-dose, rapid effect model with robust effects for treatment-resistant mental disorders and a potential advantage as a monotherapy. |
Abstract
Psychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates that psychedelics may offer a single-dose, rapid effect model that have robust effects with treatment-resistant mental disorders and a unique advantage as a possible monotherapy for mental illness. Novel clinical trials that evaluate the safety, tolerability, and efficacy in clinically representative populations are warranted.